Cardiotoxicity of trastuzumab given for 12 months compared to shorter treatment periods: a systematic review and meta-analysis of six clinical trials

BACKGROUND: Treatment de-escalation in early-stage, human epidermal growth factor receptor 2 (HER2)-positive breast cancer (BC) has been attempted in order to decrease costs and toxicities. One of the strategies pursued is decreasing trastuzumab treatment duration, with mixed results thus far. Trast...

Descripción completa

Detalles Bibliográficos
Autores principales: Eiger, Daniel, Franzoi, Maria Alice, Pondé, Noam, Brandão, Mariana, de Angelis, Claudia, Schmitt Nogueira, Melanie, de Hemptinne, Quentin, de Azambuja, Evandro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7046387/
https://www.ncbi.nlm.nih.gov/pubmed/32079624
http://dx.doi.org/10.1136/esmoopen-2019-000659

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7046387/
https://www.ncbi.nlm.nih.gov/pubmed/32079624
http://dx.doi.org/10.1136/esmoopen-2019-000659

Ejemplares similares